最新医学別冊　新しい診断と治療のABC66/精神6　認知症

出版社： 最新医学社
発行日： 2010-04-25
分野： 臨床医学：一般  >  雑誌
ISSN： 03708241
雑誌名：
特集： 認知症
電子書籍版： 2010-04-25
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,400 円(税込)

購入する

目次

  • 最新医学別冊　新しい診断と治療のABC66/精神6　認知症

    ―目次―

    特集　認知症

    第1章　概念･定義と疫学
    　概念・定義
    　疫学・一般有病率

    第2章　病理･病態生理
    　神経病理 　
    　病態生理 　
    　神経化学的基盤 　

    第3章　診断
    　代表的疾患　
    　　1.　アルツハイマー病 　
    　　2.　レビー小体型認知症 　
    　　3.　前頭側頭葉変性症（FTLD)　
    　　4.　血管性認知症 　
    　　5.　正常圧水頭症　
    　関連疾患
    　　1.　うつ病（仮性認知症） 　
    　　2.　遅発性パラフレニー 　
    　　3.　軽度認知障害 　
    　検査所見
    　　1.　神経心理学的所見 　
    　　2.　生化学的マーカー 　
    　画像所見
    　　1.　MRI 　
    　　2.　SPECT・PET 　

    第4章　管理･治療
    　薬物療法　
    　　1.　中核症状 　
    　　2.　周辺症状 　
    　　3.　新たな治療薬（ワクチン療法含む） 　
    　非薬物療法　
    　　1.　認知リハビリテーション 　
    　　2.　介護者への対応　
    　　3.　認知症の予防
    　対応
    　　1.　病名告知　
    　　2.　運転適性 　
    　　3.　成年後見 　

    第5章　ガイドライン
    　アルツハイマー病治療のガイドライン

    座談会
    　認知症：過去、現在、未来

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 概念・定義と疫学

P.15 掲載の参考文献
1) 濱中淑彦:臨床神経精神医学. 意識・知能・記憶の病理. 医学書院東京, 1986.
 
2) 博野信次:臨床認知症学入門. 金芳堂, 京都, 2007,
 
3) 山鳥重:知・情・意の神経心理学. 青灯社, 東東, 2008.
 
4) 森悦朗:4. 右半球損傷と acute confusional state. 神経心理学と画像診断 (岸本英爾, 他編) p226-233. 朝倉書店, 東京, 1988
 
5) American Psychiat Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition-Revised. American Psychiatric Association, Washington, DC, 1987.
 
6) American Psychiatric Association:Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision:DSM-IV-TR. American Psychiatric Association, Washington, DC, 2000 (高橋三郎他, 訳:DSM-IV-TR 精神疾患の診断・統計マニュアル. 医学書院東京, 2004.)
 
7) World Health Organization:The ICD-10 Classification of Mental and Behavioural Disorders:Clinical descriptions and diagnostic guidelines. World Health Organization, 1992. (融道男他, 監訳:ICD-10 精神および行動の障害-臨床記述と診断ガイドライン-. 医学書院東京, 1993.)
 
8) Cummings J L, et al:Reversible dementia:illustrative cases, definition, and review. JAMA 243:2434-2439, 1980.
 
9) Mendez M F, et al:Dementia:A Clinical Approach, Third Edition. Butterworth-Heinemann, Philadelphia, 2003,
 
10) Wancata J, et al:Diagnostic criteria influence dementia prevalence. Am J Geriatr Psychiatry 15:1034-1045, 2007.
PubMed
11) Sachdev P:Is it time to retire the term "dementia"? J Neuropsychiatry Clin Neurosci 12:276-279, 2000.
PubMed
P.23 掲載の参考文献
1) American Psychiatric Association Committee on Nomenclature and Statistics. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), Forth Edition. American Psychiatric Association:Washington DC, 1994.
 
2) McKhann G, et al:Clinical diagnosis of Alzheimer's disease:report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939-944, 1984.
 
3) Roman G C, et al:Vascular dementia:Diagnostic criteria for research studies-Report of the NINDS-AIREN International Work-group. Neurology 43:250-260, 1993.
 
4) Chui H C, et al:Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 42:473-480, 1992.
 
5) Pohjasvaara T, et al:Comparison of different clinical criteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the diagnosis of vascular dementia. National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neuro-sciences. Stroke 31:2952-2957, 2000.
 
6) Vas C J, et al:Prevalence of dementia in an urban Indian population. Int Psychogeriatr 13:439-450, 2001.
 
7) Lee D Y, et al:The prevalence of dementia in older people in an urban population of Korea:the Seoul study. J Am Geriatr Soc 50:1233-1239, 2002.
 
8) Benedetti M D, et al:Prevalence of dementia and apolipoprotein e genotype distribution in the elderly of buttapietra, verona province, Italy. Neuroepidemiology 21:74-80, 2002.
PubMed
9) Yamada T, et al:Prevalence of Alzheimer's disease, vascular dementia and dementia with Lewy bodies in a Japanese population. Psychiatry Clin Neurosci 55:21-25, 2001.
 
10) Wada-Isoe K, et al:Prevalence of dementia in the rural island town of Ama-cho, Japan. Neuroepidemiology 32:101-106, 2009.
PubMed
11) Hebert L E, et al:Alzheimer disease in the US population:prevalence estimates using the 2000 census. Arch Neurol 60:1119-1122, 2003.
PubMed
12) Lobo A, et al:Prevalence of dementia and major subtypes in Europe:A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54 (Suppl 5):S4-9, 2000.
 
13) Meguro K, et al:Prevalence of dementia and dementing diseases in Japan:the Tajiri project. Arch Neurol 59:1109-1114, 2002.
PubMed
14) Rosso S M, et al:Frontotemporal dementia in The Netherlands:patient characteristics and prevalence estimates from a population-based study. Brain 126:2016-2022, 2003
PubMed
15) Tanaka N, et al:Prevalence of possible idio-pathic normal-pressure hydrocephalus in Japan:the Osaki-Tajiri project. Neuroepidemiology 32:171-175, 2009.
 
16) Jhoo J H, et al:Prevalence of dementia and its subtypes in an elderly urban korean population:results from the Korean Longitudinal Study on Health And Aging (KLoSHA). Dement Geriatr Cogn Disord 26:270-276, 2008.
 
17) Zhang Z X, et al:Socio-demographic variation of dementia subtypes in china:Methodology and results of a prevalence study in Beijing, Chengdu, Shanghai, and Xian. Neuroepidemiology 27:177-187, 2006.
PubMed
18) Suh G H, et al:Community study of dementia in the older Korean rural population. Aust N Z J Psychiatry 37:606-612, 2003.
PubMed
19) Zhou B, et al:Prevalence of dementia in Shanghai urban and rural area. Zhonghua Liu Xing Bing Xue Za Zhi 22:368-371, 2001 [Chinese].
 
20) Hall K S, et al:Prevalence rates for dementia and Alzheimer's disease in African Americans:1992 versus 2001. Alzheimers Dement 5:227-233, 2009.
 
21) Zhou D F, et al:Prevalence of dementia in rural China:impact of age, gender and education. Acta Neurol Scand 114:273-280, 2006.
PubMed
22) de Silva H A, et al:Prevalence of dementia in a semi-urban population in Sri Lanka:report from a regional survey. Int J Geriatr Psychiatry 18:711-715, 2003.
 
23) Wangtongkum S, et al:Prevalence of dementia among population age over 45 years in Chiang Mai, Thailand. J Med Assoc Thai 91:1685-1690, 2008.
 
24) Bottino C M, et al:Estimate of dementia prevalence in a community sample from Sao Paulo, Brazil. Dement Geriatr Cogn Disord 26:291-299, 2008.
 
25) Shaji S, et al:Prevalence of dementia in an urban population in Kerala, India. Br J Psychiatry 186:136-140, 2005.
 
26) Wang W, et al:Prevalence of Alzheimer's disease and other dementing disorders in an urban community of Beijing, China. Neuroepidemiology 19:194-200, 2000.
 
27) Lyketsos C G, et al:Mental and behavioral disturbances in dementia:findings from the Cache County Study on Memory in Aging. Am J Psychiatry 157:708-714, 2000.
 
28) Ikeda M, et al:Increased prevalence of vascular dementia in Japan:a community-based epidemiological study. Neurology 57:839-844, 2001.
PubMed
29) Wakutani Y, et al:Longitudinal changes in the prevalence of dementia in a Japanese rural area. Psychogeriatrics 7:15G-154, 2007.
 
30) Yamada M, et al:Incidence of dementia, Alzheimer disease, and vascular dementia in a Japanese population:Radiation Effects Research Foundation adult health study. Neuroepidemiology 30:152-160, 2008.
 

第2章 病理・病態生理

P.34 掲載の参考文献
1) Braak H, et al:Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocyto-chemistry. Acta Neuropathol 112 (4):389-404, 2006.
 
2) Mirra S S, et al:The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41 (4):479-486, 1991.
 
3) Consensus recommendations for the post-mortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria fbr the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 18 (4 Suppl:S1-2, 1997.
 
4) Miravalle L, et al:Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques. Biochemistry 44 (32):1081 (HO821, 2005,
 
5) Takao M, et al:Anovel mutation (G217D) in the Presenilin 1 gene (PSEN1) in a Japanese family:presenile dementia and parkinsonism are associated with cotton wool plaques in the cortex and striatum. Acta Neuropathol 104 (2):155-170, 2002.
 
6) Takao M, et al:Corticobasal degeneration as cause of progressive non-fluent aphasia:clinical, radiological and pathological study of an autopsy case. Neuropathology 26 (6):569-578, 2006.
PubMed
7) Saito Y, et al:Staging of argyrophilic grains:an age-associated tauopathy. J Neuropathol Exp Neurol 63 (9):911-918, 2004.
PubMed
8) Adamec E, et al:P301L tauopathy:confocal immunofluorescence study of perinuclear aggregation of the mutated protein. J Neurol Sci 200 (1-2):85-93, 2002.
PubMed
9) Spina S, et al:Clinicopathologic features of frontotemporal dementia with progranulin sequence variation. Neurology 68 (11):820-827, 2007,
PubMed
10) Mackenzie I R, et al:Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration:consensus recommendations. Acta Neuropathol 117 (1):15-18, 2009.
PubMed
11) Munoz DG, et al:FUS pathology in basophilic inclusion body disease. Acta Neuropathol 118 (5):617-627, 2009.
PubMed
12) Neumann M, et al:Anew subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132 (Pt 11):2922-2931, 2009.
 
13) Neumann M, et al:Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. Acta Neuropathol 118 (5):605-616, 2009.
PubMed
14) Parchi P, et al:Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol 39 (6):767-778, 1996.
PubMed
15) Ghetti B, et al:Hereditary prion proteill amyloidoses. Clin Lab Med 23 (1):65-85, viii, 2003.
 
P.47 掲載の参考文献
1) Glenner G G, et al:Alzheimer's disease:initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885, 1984.
PubMed
2) Iwatsubo T, et al:Visualization of AB42 (43) and AB40 in senile plaques with end-specific AB-monoclonals:Evidence that an initially deposited species is AB42 (43). Neuron 13:45-53, 1994.
 
3) Tomita T, et al:The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid B protein ending at the 42nd (or 43rd) residue. Proc Natl Acad Sci USA 94:2025-2030, 1997.
PubMed
4) Lesne S, et al:A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440:352-357, 2006.
PubMed
5) Tomiyama T, et al:A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol 63:377-387, 2008.
PubMed
6) Togo T, et al:Immunohistochemical study of tau accumulation in early stages of Alzheimer-type neurofibrillary lesions. Acta Neuropathol 107:504-508, 2004.
PubMed
7) Lippa C F, et al:DLB and PDD boundary issues. Neurol 68:812-819, 2007.
 
8) 小阪憲司, 他:Lewy小体病の臨床病理学的研究. 精神誌82:292-311, 1980.
 
9) Obi K, et al:Relationship of phosphorylated alpha-synuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies. Exp Neurol 210:409-420, 2008.
PubMed
10) Arai T, et al:TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351:602-611, 2006.
PubMed
11) Neumann M, et al:Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130-133, 2006.
 
12) Mackenzie I R, et al:Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration:an update. Acta Neuropathol 119:1-4, 2010,
PubMed
P.58 掲載の参考文献
1) Haba K, et al:A method for parallel determination of choline acetyltransferase and muscarinic cholinergic receptors:application in aged-rat brain. Neurochem Res 13:951-955, 1988.
PubMed
2) Springer J E, et al:Regional analysis of age-related changes in the cholinergic system of the hippocampal formation and basal forebrain of the rat. Brain Res 407:180-184, 1987.
PubMed
3) Hernandez-Hernandez A, et al:Preservation of acetylcholine muscarinic M2 receptor G-protein interactions in the neocortex of patients with Alzheimer's disease. Neurosci Lett 186:57-60, 1995.
PubMed
4) Aquilonius S M, et al:Effect of denervation on acetylcholine synthesizing activity and nicotine-like binding sites in rat hind limb muscles, Acta Physiol Scand 114:345-350, 1982.
PubMed
5) Bowen D M, et al:Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99:459-496, 1976.
PubMed
6) Davies P, et al:Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2 (8000):1403, 1976.
 
7) Perry E K, et al:Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci 34:247-265, 1977.
 
8) Perry R H, et al:Senile dementia of Lewy body type;A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 95:119-139, 1990.
PubMed
9) Atack J R, et al:Molecular forms of acetylcholinesterase in senile dementia of Alzheimer type:selective loss of the intermediate (10S) fbrm. Neurosci Lett 40:199-204, 1983.
 
10) Mash D C, et al:Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 228 (4703):1115-1117, 1985.
PubMed
11) Vanderheyden P, et al:Muscarinic cholinergic receptor subtypes in normal human brain and Alzheimer's presenile dementia. J Neurol Sci 82:257-269, 1987.
PubMed
12) Shimohama S, et al:Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia. J Neurochem 46:288-293, 1986.
PubMed
13) Nordberg A, et al:The role of nicotinic receptors in the pathophysiology of Alzheimer's disease. Prog Brain Res 79:353-362, 1989.
PubMed
14) Rogers S L, et al:A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 50:136-145, 1998.
 
15) Gottfries CG, et al:Acid monoamine metabolites in human cerebrospinal fluid and their relations to age and sex. Neuropharmacology 10:665-672, 1971.
PubMed
16) Sawada M, et al:Tyrosine hydroxylase, tryptophan hydroxylase, biopterin, and neopterin in the brains of normal controls and patients with senile dementia of Alzheimer type. J Neurochem 148:760-764, 1987.
 
17) Patel V, et al:Aggressive behavior in elderly people with dementia; A review. Int J Geriatr Psychiat 8:457-472, 1993.
 
18) Zubenko G S, et al:Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol 48:619-624, 1991.
PubMed
19) Morgan D G, et al:Dopamine and serotonin systems in human and rodent brain:effects of age and neurodegenerative disease. J Am Geriatr Soc 35:334-345, 1987.
PubMed
20) Morgan D G, et al:Dopaminergic changes in the basal ganglia. A generalized phenomenon of aging in mammals. Ann N Y Acad Sci 515:145-160, 1988.
PubMed
21) Roth G S, et al:Peculiarities of the effect of hormones and transmitters during aging:modulation of changes in dopaminergic action. Gerontology 34:22-28, 1988.
PubMed
22) Cross A J, et al:Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease. Br Med J (Clin Res Ed) 282:93-94, 1981.
PubMed
23) Cross A J, et al:Monoamine metabolism in senile dementia of Alzheimer type. J Neurol Sci 60:383-392, 1983.
PubMed
24) Vassar R, et al:Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286 (5440):735-741, 1999.
PubMed
25) Takasugi N, et al:The role of presenilin co-factors in the gamma-secretase complex. Nature 422 (6930):438-441, 2003.
 
26) Jarrett J T, et al:The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation:implications for the pathogenesis of Alzheimer's disease. Biochemistry 32:4693-4697, 1993.
PubMed
27) Goate A, et al:Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349 (6311):704-706, 1991.
PubMed
28) Suzuki N, et al:An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264 (5163):1336-1340, 1994.
PubMed
29) Sherrington R, et al:Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375 (6534):754-760, 1995.
PubMed
30) Levy-Lahad E, et al:Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269 (5226):973-977, 1995.
PubMed
31) Goedert M, et al:Tau proteins of Alzheimer paired helical filaments:abnormal phosphorylation of all six brain isofbrms. Neuron 8:159-168, 1992.
PubMed
32) Kopke E, et al:Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem 268:243742-24384, 1993.
PubMed
33) Morishima-Kawashima M, et al:Proline-directed and non-proline-directed phosphorylation of PHF-tau. J Biol Chem 270:823-829, 1995.
 
34) Baumann K, et al:Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett 336:417-424, 1993.
PubMed
35) Hanger D P, et al:Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau:generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett 147:58-62, 1992.
PubMed
36) Roder HM, et al:Brain protein kinase PK40erk converts TAU into a PHF-like form as found in Alzheimer's disease. Biochem Biophys Res Commun 193:639-647, 1993.
 
37) Gong CX, et al:Phosphoprotein phos-phatase activities in Alzheimer disease brain. J Neurochem 61:921-927, 1993.
 
38) Perry G, et al:Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc Natl Acad Sci USA 84:3033-3036, 1887.
 
39) Hutton M, et al:Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393:702-705, 1998.
PubMed
40) Ueda K, et al:Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 90:11282-11286, 1993.
PubMed
41) Zarranz J J, et al:The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55:164-173, 2004.
PubMed
42) Neumann M, et al:Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314 (5796):130-133, 2006.
PubMed
43) Arai T, et al:TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351:602-611, 2006.
PubMed

第3章 診断

P.70 掲載の参考文献
1) 田邉敬貴:痴呆の症候学. 医学書院, 東京, 2001.
 
2) 松田実他:人との関係性からみた認知症症候学. 老年精医誌 20 (増刊-I):104-112, 2009.
 
3) 仲秋秀太郎, 他:Alzheimer 型痴呆における遠隔記憶に関する研究-自伝的記憶の検査, Dead/Alive test による検討失語症研18:293-303, 1998.
 
4) 吉益春夫, 他:プライステストについて;簡便な逆向性健忘検査のコルサコフ症候群への応用. 精神医 39:729-733, 1977.
 
5) 山鳥 重:記憶の神経心理学. 医学書院, 東京, 2002.
 
6) Nagahama Y, et al:Classification of psychotic symptoms in dementia with Lewy bodies. Am J Geriatr Psychiatry 15:961-967, 2007.
PubMed
7) Ikeda M, et al:Delusions of Japanese patients with Alzheimer's disease. Int J Geriatr Psychology 18:527-532, 2003.
 
8) Frisoni G B, et al:The topography of grey matter involvement in early and late onset Alzheimer's disease. Brain 130:720-730, 2007.
 
9) Sakamoto S, et al:Differences in cerebral metabolism between early and late onset types of Alzheimer's disease. J Neurol Sci 200:27-32, 2002.
 
10) Schneider J, et al:Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69:2197-2204, 2007.
PubMed
11) Ikeda K, et al:Clinical aspects of argyrophilic grain disease. Clin Neuropathol 19:278-284, 2000.
 
12) Jellonger K A, et al:Nurofibrollary tangle-dredominant dementia:comparison with classical Alzheimer disease. Acta Neuropathol 113:107-117, 2007.
 
13) Haxby J V, et al:Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch Neurol 47:753-760, 1990.
PubMed
14) Gorno-Tempini M L, et al:Cognition and anatomy in three variants of primary proressive aphasia. Ann Neurol 55:335-346, 2004.
PubMed
15) Alladi S, et al:Focal presentations of Alzheimer's disease. Brain 130:2636-2645, 2007.
PubMed
16) Johnson J K, et al:Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol 56:1233-1239, 1999.
PubMed
17) Benson D F, et al:Posterior cortical atrophy. Arch Neurol 45:789-793, 1988.
PubMed
18) Levine DN, et al:The visual variant of Alzheimer's disease:a clinicopathologic study. Neurology 43:305-313, 1993.
 
19) McKhann G, et al:Clinical diagnosis of Alzheimer's disease:Report of the NINCDS-ADRDA work group under the auspieces of Department of Health Services Task Force on Alzheimer's disease. Neurology 34:939-944, 1984.
 
20) Dubois B, et al:research criteria fbr the diagnosis of Alzheimer's disease:revising NINCDS-ADRDA criteria. Lancet Nerol 6:734-746, 2007.
 
P.80 掲載の参考文献
1) McKeith I G, et al:Diagnosis and management of dementia with Lewy bodies:third report of the DLB Consortium. Neurology 65:1863-1872, 2005.
PubMed
2) Takahashi S, et al:Depression associated with dementia with Lewy bodies (DLB) and the effect of somatotherapy. Psychogeriatrics 9:56-61, 2009.
PubMed
3) Borroni B, et al:Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB):Frequency and relationship with disease severity and motor impairment. Arch Gerontol Geriatr 46:101-106, 2008.
PubMed
4) Horimoto Y, et al:Autonomic dysfunctions in dementia with Lewy bodies. J Neurol 250:530-533, 2003.
PubMed
5) Mizukami K, et al:Decreased ventilatory response to hypercapnia in dementia with Lewy bodies. Ann Neurol 65:614-617, 2009.
PubMed
6) Minoshima S, et al:Alzheimer's disease versus dementia with Lewy bodies:cerebral metabolic distinction with autopsy confirmation. Ann Neurol 50:358-365, 2001.
PubMed
7) Yoshita M, et al:Value of 1231-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 66:1850-1854, 2006.
 
8) 本間敏明, 他:Lewy 小体型認知症における呼吸化学調節機能の検討. 日呼吸会誌 45:297-300, 2007.
Medical*Online
P.91 掲載の参考文献
1) Pick A:Uber die Benziehungen der senile Hirnatrophie zur Aphasie. Prag Med Wochenschr 17:165-167, 1892.
 
2) Neary D, et al:Frontotemporal lobar degeneration;A consensus on clinical diagnostic criteria. Neurology 51:1546-1554, 1998.
 
3) Knopman D S, et al:Antemortem deagnosis of frontotemporal lobar degeneration. Ann Neurol 57:480-488, 2005.
 
4) Mendez M F, et al:Stereotypical movements and frontotemporal dementia. Mov Disord 20:742-745, 2005.
PubMed
5) Shigenobu K, et al:The Stereotypy Rating Inventory for frontotemporal lobar degeneration. Psychiatry Res 110:175-187, 2002.
PubMed
6) Bozeat S, et al:Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer's disease? J Neurol Neurosurg Psychiatry 69:178-186, 2000.
 
7) Ikeda M, et al:Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer's disease. J Neurol Neurosurg Psychiatry 73:371-376, 2002.
 
8) Hirono N, et al:Distinctive neurobehavioral features among neurodegenerative dementias. J Neuropsychiatry Clin Neurosci 11:498-503, 1999.
PubMed
9) Mendez M F, et al:Psychotic symptoms in frontotemporal dementia:prevalence and review. Dement Geriatr Cogn Disord 25:206-211, 2008.
PubMed
10) 大槻美佳:Anarthrie の症候学. 神心理 21:172-182, 2005.
 
11) 大槻美佳:失語症の定義とタイプ分類. 神経内科68 (5):155-165, 2008.
 
12) 田邉敬貴, 他:語義失語と意味記憶障害. 失語症研 12:153-167, 1992.
 
13) Snowden J S, et al:Distinct behavioural profiles in frontotemporal dementia and semantic dementia. J Neurol Neurosurg Psychiatry 70:323-332, 2001.
PubMed
14) Rose H J, et al:Behavioral features in semantic dementia vs other forms of progressive aphasias. Neurology 67:1752-1756, 2006.
 
P.105 掲載の参考文献
1) Brand F N et al:Relationship of cere-brovascular disease to senile, presenile and cereberal arteriosclerotic dementia. J Chronic Dis 24:569-583, 1971.
 
1) Fisher C M:Dementiain cerebrovascu;ar disease. Cerebrovascular Diseases (Tool JF, et al, eds) pp232-236. Grune & Stratton, New York, 1968
 
2) Hachinski V C, et al:Cerebral blood flow in dementia. Arch Neurol 32:632-637, 1975.
PubMed
3) Roman G C, et al:Vascular dementia;diagnostic criteria for research studies, Report of the NINDS-AIREN international Workshop. Neurology 43:25G260, 1993.
 
4) Chui H C, et al:Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 42:473-480, 1992.
 
5) Wold Health Organization:ICD-10 classification of mental and behavioral disoerders:Diagnositic criteria for research. WHO, Geneva, 1993.
 
6) American Psychiatric Association:Diagnostic and statistical manual of mental disorders (4th ed), Washington DC, 1994.
 
7) Nagata K et al:Clinical diagnosis of vascular dementia. J Neurol Sci 257:44-48, 2007.
PubMed
P.115 掲載の参考文献
1) Adams R D, et al:Symptomatic Occult Hydrocephalus with "Normal" Cerebrospinal-Fluid Pressure. a Treatable Syndrome. N Engl J Med 273:117-126, 1965.
PubMed
2) 日本正常圧水頭症研究会特発性正常圧水頭症診療ガイドライン作成委員会編:特発性正常圧水頭症診療ガイドライン. メディカルレビュー社, 大阪 2004.
 
3) Ishikawa M, et al:Guidelines for management of idiopathic normal pressure hydrocephalus. Neurol Med Chir (Tokyo) 48 (Suppl):S1-23, 2008.
PubMed
4) Marmarou A, et al:Development of guidelines for idiopathic normal-pressure hydrocephalus:introduction. Neurosurgery 57:S1-3 discussion ii-v, 2005.
 
5) Bech-Azeddine R, et al:Idiopathic normal-pressure hydrocephalus:evaluation and findings in a multidisciplinary memory clinic. Eur J Neurol 8:601-611, 2001.
 
6) Iseki C, et al:Asymptomatic ventriculomegaly with features of idiopathic normal pressure hydrocephalus on MRI (AVIM) in the elderly:A prospective study in a Japanese population. J Neurol sci 277 (1-2):54-57, 2009.
 
7) Stolze H, et al:Gait analysis in idiopathic normal pressure hydrocephalus;Which parameters respond to the CSF tap test? Clin Neurophysiol 111:1678-1686, 2000.
 
8) Stolze H, et al:Comparative analysis of the gait disorder of normal pressure hydrocephalus and Parkinson's disease. J Neurol Neurosurg Psychiatry 70:289-297, 2001.
PubMed
9) Miyoshi N, et al:Association between cognitive impairmellt and gait disturbance in patients with idiopathic normal pressure hydrocephalus. Dement Geriatr Cogn Disord 20:71-76, 2005.
PubMed
10) Ogino A, et al:Cognitive impairment in patients with idiopathic normal pressure hydrocephalus. Dement Geriatr Cogn Disord 21:113-119, 2006.
PubMed
11) Thomas G, et al:Baseline neuropsychological profile and cognitive response to cerebrospinal fluid shunting for idiopathic normal pressure hydrocephalus. Dement Geriatr Cogn Disord 20:163-168, 2005.
PubMed
12) 榊原隆次, 他:特発性正常圧水頭症の排尿障害. RRAIN and NERVE 60:233-239, 2008.
 
13) Kito Y, et al:Neuropsychiatric symptoms in patients with idiopathic normal pressure hydrocephalus. Behav Neurol 21:165-174, 2009.
PubMed
14) Kitagaki H, et al:CSF spaces in idiopathic normal pressure hydrocephalus:morphology and volumetry. AJNR Am J Neuroradiol 19:1277-1284, 1998.
 
15) Oi S, et al:Pathophysiology of long-standing overt ventriculomegaly in adults. J Neurosurg 92:933-940, 2000.
PubMed
16) Kubo Y, et al:Validation of grading scale for evaluating symptoms of idiopathic normal pressure hydrocephalus. Dement Geriatr Cogn Disord 25:37-45, 2008.
PubMed
P.124 掲載の参考文献
1) Emery V O B, et al:Update on the dementia spectrum of depression. Am J Psychiatry 149:305-317, 1992.
 
2) 馬場元, 他:うつ病性仮性認知症. 精神科治療 21:1075-1082, 2006.
 
3) Ganser S J M:Uber einen eigenartigen hysterischen Dammerzustand. Arch Psychiatr Nervenkr 30:633-640, 1998.
 
4) Kiloh L G:Pseudo-dementia. Acta Psychiatr Scand 37:336-351, 1961.
PubMed
5) Barrios G E:"Depressive pseudodementia" or "Melancholic dementia":a 19th century view. J Neurol Neurosurg Psychiatry 48:393-400, 1985.
 
6) 馬場元:精神科における専門外来の試み新たな展開とその今日的意義老年期うつ病外来. 精神科治療 23:1109-1113, 2008.
 
7) 馬場奏子, 他:Alzheimer 病とうつ病成人病と生活習慣病 36:308-313, 2006.
 
8) Djernes J K:Prevalence and predictors of depression in populations of elderly:a review. Acta Psychiatr Scand 113:372-387, 2006.
PubMed
9) Fujikawa T, et al:Incidence of silent cerebral infarction in patients with major depression. Stroke 24:1631-1634, 1993.
PubMed
10) Alexopoulos G S, et al:Clinically defined vascular depression. Am J psychiatry 154:562-565, 1997.
PubMed
11) Wragg R E, et al:Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry 146:577-587, 1989.
PubMed
12) Cummings J L, et al:Neuropsychiatric aspects of multi-infarct dementia and dementia of the Alzheimer's type. Arch Neurol 44:389-393, 1987.
PubMed
13) Kessing L V, et al:Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry 75:1662-1666, 2004.
PubMed
14) Dobie D J:Depression, dementia, and pseudodementia. Semin Clin Neuropsychiatry 7:170-186, 2002.
PubMed
15) Nakano Y, et al:Executive dysfunction in medicated, remitted state of major depression. J Affect Disord 111:46-51, 2008
PubMed
16) Baba K, et al:Executive Dysfunction in Remitted Late-Life Depression:Juntendo University Mood Disorder Projects (JUMP). J Neuropsychiatry Clin Neurosci 22 (1):70-74, 2010.
 
17) 森 秀樹, 他:認知症と鑑別すべき病態-低活動性せん妄, 仮性認知症と軽度認知障害を中心に-. 精神科治療 20:1013-1021, 2005.
 
18) 山本英樹, 他:鑑別困難例に対する初期治療とその対応-うつ病の場合-. 精神科治療 20:999-1004, 2005.
 
19) 馬場元:老年期うつ病総論-神経心理学的検査. 老年期うつ病ハンドブック (三村將監), p85-89. 診断と治療社, 東京, 2009.
 
20) 松田博史:アルツハイマー病, レビー小体病とうつ病の画像診断. 精神科 11:14-20, 2007.
 
P.130 掲載の参考文献
1) Howard R, et al:Late-Onset Schizophrenia. Wrightson Biomedical Pub, Petersfield, 1999.
 
2) Howard R, et al:Late-Onset Schizophrenia and Very-Late-Onset Schizophrenia-like Psychosis:An International Consensus. Am J Psychiat 157:172-178, 2000.
PubMed
3) 古茶大樹:初老期・老年期の Psychose の歴史と現状. 精神科治療 19:295-303, 2004.
 
4) Roth M:Late Paraphrenia. In:Schizophrenia And Aging (Miller NE, et al, eds). pp217-234. Guilford, New York, 1987.
 
P.138 掲載の参考文献
1) Petersen R C, et al:Mild cognitive impairment;Clinical characterization and outcome. Arch Neuro 56:303-308, 1999.
PubMed
2) Busse A, et al:Mild cognitive impairment; Long-term course of four clinical subtypes. Neurology 67:2176-2185, 2006.
PubMed
3) Pereira F S, et al:Executive dysfunction correlates with impaired functional status in older adults with varying degrees of cognitive impairment. Int Psychogeratr 20:1104-1115, 2008.
PubMed
4) Peres K, et al:Restriction in complex activities of daily living in MCI;Impact on outcome. Neurology 67:461-466, 2006.
PubMed
5) 大内義隆 他:手段的ADLの水準低下と認知症への移行. 老年精神医学雑誌 20:265-270, 2009.
Medical*Online
6) Geda Y E, et al:Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging:population-based study. Arch Gen Psychiatry 65:1193-1198, 2008.
PubMed
7) Robert P H, et al:Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer's disease;A one-year follow-up study. Clin Neurol Neurosurg 108:733-736, 2006.
PubMed
8) Levy A, et al:Mild cognitive impairment; An opportunity to identify patients and high risk fbr progression to Alzheimer's disease. Clin Ther 28:991-1001, 2006.
 
9) 石井賢二:軽度認知機能障害の画像診断. 老年精神医学雑誌 20:271-279, 2009.
 
10) Fagan A M, et al:Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid AB 42 in humans. Ann Neurol 59:512-519, 2006.
 
11) Ishikawa T, et al:A longitudinal study regarding conversion from mild memory impairment to dementia in a Japanese community. Int J Geriatr Psychiatry 21:134-139, 2006.
 
12) Larrieu S, et al:Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 59:1594-1599, 2002.
 
13) Matthew F E, et al:Two-year progression from mild cognitive impairment to dementia;To what extent do different definitions agree? J Am Geriatr Soc 56:1424-1433, 2008.
 
14) 三村將, 他:軽度認知機能障害の対応・訓練; 説明と病名告知を含めて. 老年精神医学雑誌 20:287-293, 2009.
 
P.147 掲載の参考文献
1) 加藤伸司, 他:改訂版長谷川式簡易知能評価スケール (HDS-R) の作成. 老年精医誌 2:1339-1347, 1991.
 
2) 森悦郎, 他:神経疾患患者における日本語版 Mini-Mental State テストの有用性. 神経心理 1:82-89, 1985.
 
3) Crum R M, et al:Population-based norms for the mini-mental state examination by age and education level. JAMA 269:2386-2391, 1993.
PubMed
4) Mohs R C, et al:The Alzheimer's Disease Assessment Scale;An instrument for assessing treatment ethcacy. Psychopharmacol Bull 19:448-450, 1983.
 
5) 本間昭, 他:Alzheimer's Disease Assessment Scale (ADAS) 日本語版の作成老年精医誌 3:647-655, 1992.
 
6) Rosen W, et al:A new scale for Alzheimer's disease. Am J Psychiatry 141:1356-1364, 1984.
 
7) Wechsler D 原著, 日本版 WAIS-III 刊行委員会:WAIS-III 成人知能検査法実施・採点マニュアル. 日本文化科学社, 東京, 2006.
 
8) Wechsler D, 杉下守弘訳:日本語版ウェクスラー記憶検査法 (WMS-R) 日本文化科学社, 東京, 2001.
 
9) 綿森淑子, 他:日本版リバーミード行動記憶検査 (RBMT) . 千葉テストセンター, 2002.
 
10) 鹿島晴雄, 他監:レザック神経心理学的検査集成 (Lezak MD著). 創造出版, 東京, 2005.
 
11) 加藤元一郎:前頭葉損傷における概念の形成と変換について-新修正 Wisconsin Card Sorting Test を用いた検討. 慶應医 65:861-885, 1988.
 
12) 鹿島晴雄, 他:注意障害と前頭葉損傷. 神研の進歩 30:847-858, 1986.
 
13) 斎藤寿昭, 他:前頭葉損傷と Word Fluency-特に抑制障害との関連について. 失語症研 12:223-231, 1992.
 
14) 田渕肇:軽度のもの忘れの訴え. 精神誌 111:967-972, 2009.
 
P.159 掲載の参考文献
1) Blennow K, et al:Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010[Epub ahead of print].
 
2) Mattsson N, et al:CSF biomarkers and incipient Alzheimer disease in patients with mlld cognitive impairment. JAMA 302 (4):385-393, 2009.
 
3) Shaw L M, et al:Cerebrospinal Huid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65 (4):403-413, 2009.
 
4) Petersen R C, et al:Alzheimer's Disease Neuroimaging Initiative (ADNI):clinical characterization. Neurology 74 (3):201-209, 2010.
 
5) Kanai M, et al:Longitudinal study of cerebrospinal fluid levels of tau, AB1-40, and AB1-42(43) in Alzheimer's disease:a study in Japan. Ann Neurol 44 (1):17-26, 1998.
 
6) Shoji M, et al:Cerebrospinal fluid tau in dementia disorders:a large scale multicenter study by a Japanese study group. Neurobiol Aging 23 (3):363-370, 2002.
 
7) Itoh N, et al:Large-scale, multicenter study of cerebrospinal nuid tau protein phosphorylated at serine 199 fbr the antemortem diagnosis of Alzheimer's disease. Ann Neurol 50 (2):150-156, 2001.
 
8) Hampel H, et al:Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease:acomparative cerebrospinal fiuid study. Arch Gen Psychiatry 61 (1):95-102, 2004.
 
9) Blennow K, et al:CSF markers for incipient Alzheimer's disease. Lancet Neurol 2 (10):605-613, 2003.
PubMed
10) Visser P J, et al:Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment ormild cognitive impairment in the DESCRIPA study:a prospective cohort study. Lancet Neurol 8 (7):619-627, 2009.
 
11) Stomrud E, et al:Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol 67 (2):217-223, 2010.
PubMed
12) Fagan A M, et al:Cerebrospinal fluid tau and ptau (181) increase with cortical amyloid deposition in cognitively normal individuals:implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 1 (8-9):371-380, 2009.
 
13) Snider B J, et al:Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol 66 (5):638-645, 2009.
PubMed
14) Lannfelt L, et al:Safety, efficacy, and bio-marker findings of PBT2 in targeting AB as a modifying therapy for Alzheimer's disease:a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7 (9):779-786, 2008.
 
15) Tapiola T, et al:Cerebrospinal fluid B-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66 (3):382-389, 2009.
 
16) Schupf N, et al:Peripheral AB subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci USA 105 (37):14052-14057, 2008.
 
17) van Oijen M, et al:Plasma AB (1-40) and AB (1-42) and the risk of dementia:a prospective case-cohort study. Lancet Neurol 5 (8):655-660, 2006.
 
18) Graff-Radford N R, et al:Association of low plasma AB42/AB40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64 (3):354-362, 2007,
 
19) Kawarabayashi T, et al:Plasma biomarkers of Alzheimer's disease. Curr Opin Psychiatry 21 (3):260-267, 2008.
 
20) Ray S, et al:Classification and prediction ofclinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13 (11):1359-1362, 2007.
 
P.168 掲載の参考文献
1) Jack C R Jr, et al:Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 49 (3):786-794, 1997.
PubMed
2) Ashburner J, et al:Voxel based morphometry-the methods. Neuroimage 11 (6):805-821, 2000.
 
3) Hirata Y, et al:Voxel-based morphometry to discriminate early Alzheimer's disease from controls. Neurosci Lett 382 (3):269-274, 2005.
PubMed
4) 松田博史:早期アルツハイマー病診断支援システムVSRADについて. 日放技会誌 62 (8):1066-1072, 2005.
 
5) Leow A D, et al:ADNI Preparatory Phase Study. Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. Neuroimage 31 (2):627-640, 2006.
PubMed
6) Matsunari L et al:Comparison of 18F-FDG PET and optimized voxel-based morphom:etry for detection of Alzheimer's disease:aging effect on diagnostic performance. J Nucl Med 48 (12):1961-1970, 2007.
 
7) Matsuda H:Role of neuroimaging in Alzheimer's disease, with emphasis on brain perfusion SPECT. J Nucl Med 48 (8):1289-1300, 2007.
 
8) Ferreira L K, et al:Neurostructural predictors of Alzheimer's disease:A meta-analysis of VBM studies. Neurobiol Aging doi:10. 1016/j.neurobiolaging.2009.11.008
 
9) Yuan Y, et al:Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment:a meta-analysis. AJNR Am J Neuroradiol 30 (2):404-410, 2009.
PubMed
10) Krishnan K R, et al:Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 160 (11):2003-2011, 2003.
PubMed
11) Hashimoto M, et al:Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am J Psychiatry 162 (4):676-682, 2005.
 
12) Jack C R Jr, et al:Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging 29 (9):1285-1295, 2008.
PubMed
13) Venneri A, et al:Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease. Neuroreport 16 (2):107-110, 2005.
 
14) 山田実, 他:アルツハイマー病対策プロジェクト (J-ADNI) におけるMRIの役割. INNERVISION 23 (9):60-61, 2008.
Medical*Online
15) Burton E J, et al:Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage 17 (2):618-630, 2002.
PubMed
16) Whitwell JL, et al:Focal atrophy in dementia with Lewy bodies on MRI:adistinct pattern from Alzheimer's disease. Brain 130 (3):708-719, 2007.
 
17) Burton EJ, et al:Cerebral atrophy in Parkinson's disease with and without dementia:a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 127 (4):791-800, 2004.
 
18) Pereira J M, et al:Atrophy patterns in histologic vs clinical groupings of frontotemporal lobar degeneration. Neurology 72 (19):1653-1660, 2009.
 
19) Yamashita F, et al:Detection of changes incerebrospinal fluid space in idiopathic normal pressure hydrocephalus using voxelbased morphometry. Neuroradiology DOI 10.1007/s00234-009-0610-z
 
20) Ashburner J:A fast diffeomorphic image registration algorithm. Neuroimage 38 (1):95-113, 2007.
PubMed
P.178 掲載の参考文献
1) Minoshima S, et al:A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET, J Nucl Med 36:1238-1248, 1995.
 
2) Silverman D H:Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias:comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 45:594-607, 2004.
 
3) Klunk W E, et al:Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55:306-319, 2004.
PubMed
4) 石井賢二:アミロイドイメージング. Annual Review 神経 2010 (鈴木則弘, 他編) pp57-64. 中外医学社, 東京, 2010.
 
5) Yoshita M, et al:A clinical role for [123I] MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 71:583-588, 2001.
 
6) Alzheimer's Disease Neuroimaging Initiative:(http://www.loni.ucla.edu/ADM, http://www.j-adni.org)
 

第4章 管理・治療

P.191 掲載の参考文献
1) Homma A, et al:Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population:results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord 25:399-407, 2008
 
2) Homma A, et al:Long-Term Safety and Efficacy of Donepezil in Patients with Severe Alzheimer's Disease:Results from a 52-Week, Open-Label, Multicenter, Extension Study in Japan. Dement Geriatr Cogn Disord 7:232-239, 2009.
 
3) 独立行政法人医薬品医療機器総合機構:審査報告書 (一般名:塩酸ドネペジル), 平成 19 年 7 月10 日,
 
4) 岸本年史他:[介護保健における痴呆患者のケアの実態と評価に関する調査研究・広報啓発事業] 介護保健施設における痴呆患者の介護医療の実態と評価に関する研究-痴呆療養病棟における痴呆患者ケアの実態に関する研究-. 2002.
 
5) Reisberg B, et al:Senile dementia of the Alzheimer type:diagnostic features with special reference to functional assessment staging. In:Senile dementia of the Alzheimer type. Vol 2 (Traber J, et al, eds). pp18-37. Springer-Verlag, Berlin, 1985.
 
6) 鈴木千絵子, 他:unpublished data.
 
7) 中村祐:認知症の経過・予後:薬物療法と長期経過・予後. 老年精医誌 20 (6):630-639, 2009.
 
P.208 掲載の参考文献
1) Matsumoto N, et al:Caregiver burden associated with behavioral and psychological symptoms of dementia in elderly people in the local community. Dement Geriatr Cogn Disord 23:219-224, 2007.
PubMed
2) Matsui T, et al:Determinants of the quality of life in Alzheimer's disease patients as assessed by the Japanese version of the Quality of Life-Alzheimer's disease scale. Dement Geriatr Cogn Disord 21:182-191, 2006.
 
3) Schneider LS, et al:Risk of death with atypical antipsychotic drug treatment for dementia:meta-analysis of randomized placebo-controlled trials. JAMA 294:1934-1943, 2005.
PubMed
4) Wang PS, et al:Risk of death in elderly users of conventional vs. a typical antipsychotic medications. N Engl J Med 353:2335-2341, 2005.
 
5) Kales H C, et al:Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 164:1568-1576, 2007.
PubMed
6) Douglas IJ, et al:Exposure to antipsychotics and risk of stroke:self controlled case series study. BMJ 337:a1227, 2008.
PubMed
7) Liperoti R, et al:All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia:a retrospective cohort study. J Clin Psychiatry 70:1340-1347, 2009.
PubMed
8) Zaccai J, et al:A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 34:561-566, 2005.
PubMed
9) Wakisaka Y, et al:Age-associated prevalence and risk factors of Lewy body pathology in a general population:the Hisayama study. Acta Neuropathol 106:374-382, 2003.
 
10) Hirono N, et al:Neuropsychiatric aspects of dementia with Lewy bodies. Curr Psychiatry Rep 1:85-92, 1999.
 
11) Buracchio T, et al:Dementia with Lewy bodies:current concepts. Dement Geriatr Cogn Disord 20:306-320, 2005.
PubMed
12) Piggott M A, et al:Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases:rostrocaudal distribution. Brain 122:1449-1468, 1999.
 
13) 眞鍋雄太, 他:レビー小体型認知症の周辺症状における高用量ドネペジルの有用性精神医 51:1165-1172, 2009.
 
14) McKeith I, et al:Efficacy of rivastigmine in dementia with Lewy bodies:a randomised, double-blind, placebo-controlled international study. Lancet 356:2031-2036, 2000.
 
15) Edwards K R, et al:Efficacy and safety of galantamine in patients with dementia with Lewy bodies:a 12-week interim analysis. Dement Geriatr Cogn Disord 17 (Suppl 1):40-48, 2004.
 
16) Mori S, et al:Efficacy and safety of donepezil in patients with dementia with Lewy bodies:preliminary findings from an open-label study. Psychiatry Clin Neurosci 60:190-195, 2006.
PubMed
17) Aarsland D, et al:Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies:a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 8:613-618, 2009.
 
18) Iwasaki K, et al:Effects of the traditional Chinese herbal medicine Yi-Gan San for cholinesterase inhibitor-resistant visual hallucinations and neuropsychiatric symptoms in patients with dementia with Lewy bodies. J Clin Psychiatry 66:1612-1613, 2005.
PubMed
19) McKeith I G, et al:Consortium on DLB. Diagnosis and management of dementia with Lewy bodies:third report of the DLB Consortium. Neurology 65:1863-1872, 2005.
 
20) Massironi G, et al:Drug treatment of REM sleep behavior disorders in dementia with Lewy bodies. Int Psychogeriatr 15:377-383, 2003.
PubMed
21) Schneider L S, et al:CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 355:1525-1538, 2006.
 
22) Sultzer DL, et al:CATIE-AD Study Group, Clinical symptom responses to a typical antipsychotic medications in Alzheimer's disease:phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 165:844-854, 2008.
 
23) Zheng L, et al:Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients:the CATIE-AD study. Am J Psychiatry 166:583-590, 2009.
 
24) Deberdt W G, et al:Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry 13:722-730, 2005.
PubMed
25) Mintzer J, et al:Risperidone in the treatment of psychosis of Alzheimer disease:results from a prospective clinical trial. Am J Geriatr Psychiatry 14:280-291, 2006.
PubMed
26) Pollock B G, et al:A double-blnd comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 15:942-952, 2007.
 
27) Howard RJ, et al:CALM-AD Trial Group. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 357:1382-1392, 2007.
PubMed
28) Mintzer JE, et al:Aripiprazole fbr the treatment of psychoses in institutionalized patients with Alzheimer dementia:a multicenter, tandomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry 15:918-931, 2007.
 
29) Streim J E, et al:A randomized, doubleblind, placebo-controlled study of aripiprazole fbr the treatment of psychosis in nursing home patients with Alzheimer disease. Am J Geriatr Psychiatry 16:537-550, 2008.
 
P.221 掲載の参考文献
1) Mori S, et al:Efficacy and safety of donepezil in patients with dementia with Lewy bodies:preliminary findings from an open-label study. Psychiatry Clin Neurosci 60 (2):190-195, 2006.
PubMed
2) Raschetti R, et al:Cholinesterase inhibitors in mild cognitive impairment:a systematic review of randomised trials. PLoS Med 4 (11):1818-1828, 2007.
 
3) Caccamo A, et al:MI agonists as a potential disease-modifying therapy for Alzheimer's disease. Curr Alzheim Res 6 (2):112-117, 2009.
 
4) Wang H Y, et al:Dissociating beta-amyloid from alpha 7 nicotinic acetylcholine receptor by a novel therapeutic agent, S 24795, normalizes alpha 7 nicotinic acetylcholine and NMDA receptor function in Alzheimer's disease brain. J Neurosci 29 (35):10961-10973, 2009.
 
5) Doody R S, et al:Effect of dimebon on cognition, activities of daily hving, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease:a randomised, double-blind, placebo-controled study. Lancet 372 (9634):207-215, 2008.
 
6) Steele J W, et al:Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo. Mol Neurogener 4:51, 2009.
 
7) Katz A, et al:Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. J Clin Pharmacol 49 (6):643-649, 2009.
PubMed
8) Fisher A:MI muscarinic agonists target major hallmarks of Alzheimer's disease-the pivotal role of brain MI receptors. Neurodegenerative Dis 5:237-240, 2008.
 
9) Tabira T:Clioquinol:s return:cautions from Japan. Science 292 (5525):2251-2252, 2001.
 
10) Lannfelt L, et al:Safety, efficacy, and bio-marker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease:a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7:779-786, 2008.
 
11) Hawkes C A, et al:Small molecule beta-amyloid inhibitors that stabilize protofibrillar structures in vitro improve cognition and pathology in a mouse model of Alzheimer's disease. Eur J Neurosci 31 (2):203-213, 2010.
 
12) Salloway S, et al:A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73:2061-2070, 2009.
PubMed
13) Yamada K, et al:Abeta immunotherapy:intracerebral sequestration of Abeta by an anti-Abeta monoclonal antibody 266 with high affinity to soluble Abeta. J Neurosci 29 (36):11393-11398, 2009.
PubMed
14) Tabira T:Immunization therapy for Alzheimer disease:A comprehensive review of active immunization strategies. Tohoku J Exp Med 220 (2):95-106, 2010.
PubMed
15) Hara H, et al:Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. J Alzheim Dis 6 (5):483-488, 2004.
 
16) Mouri A, et al:Oral vaccination with a recombinant adeno-associated viral vector attenuates age-related Abeta accumulation and memory deficits without lymphocytic infiltration in Tg2576 mice. FASEB J 21 (9):2135-2148, 2007.
PubMed
17) Schneeberger A, et al:Development of AFFITOPE vaccines for Alzheimer's disease (AD)-from concept to clinical testing. J Nutr Health Aging 13 (3):264-267, 2009.
PubMed
18) Wischik C, et al:Challenges in the conduct of disease-modifying trials in AD:practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy. J Nutr Health Aging 13 (4):367-369, 2009.
PubMed
19) Gozes I, et al:Addressing Alzheimer's disease tangles:from NAP to AL-108, Curr Alzheim Res 6 (5):455-460, 2009.
 
20) Sereno L, et al:Anovel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol Dis 35 (3):35S-367, 2009.
 
P.227 掲載の参考文献
1) Kawashima R, et al:Reading aloud and arithmetic calculation improve frontal function of people with dementia. J Gerontol A Biol Sci Med Sci 60:380-384, 2005.
PubMed
2) 吉田甫他:学習課題の遂行が老年期痴呆患者の認知機能に及ぼす効果. 老年精医誌 15:319-325, 2004.
Medical*Online
3) Matsuda O:Cognitive stimulation therapy for Alzheimer's disease:Effect of cognitive stimulation therapy on the progression of mild Alzheimer's disease in patiellts treated with donepezil. Inter Psychogeriatrics 19:241-252, 2007.
 
4) 松田修:若年性アルツハイマー病に対する心理教育的配慮に基づく認知リハビリテーションの事例. 心理臨床研24:559-570, 2006.
 
5) Clare L, et al:Errorless learning of face-name associations in early Alzheimer's disease. Neurocase 5:37-46, 1999.
 
6) 森朋子, 他:軽度～中等度アルツハイマー型認知症への認知リハビリテーションの効果判定. 老年精医誌 19:891-899, 2008.
Medical*Online
7) 松田修:記憶訓練法. くすりに頼らない認知症治療I:非薬物療法のすべて (深津亮他編) . p133-146. ワールドプランニング, 東京, 2009.
 
8) 松田修:お年寄りと家族のためのソーシャルスキル. サイエンス社, 東京, 2004.
 
9) Chapman S B, et al:Effects of cognitive communication stimulation for Alzheimer's disease patients treated with donepezil. J Speech Lang Hear Res 47:1149-1163, 2004.
PubMed
10) De Vreese L P, et al:Effect size of a three-month drug treatment in AD when combined with individual cognitive retraining:Preliminary results of a pilot study. Eur Arch Psychiatry Clin Neurosci 248:S41-S42, 1998.
 
11) Requena C, et al:Effects of cholinergic drugs and cognitive training on dementia. Dement Geriatr Cogn Disord 18:50-54, 2004.
PubMed
P.234 掲載の参考文献
1) 小澤勲:物語としての痴呆ケア, p31. 三輪書店, 東京, 2004.
 
2) 尾之内直美:日本痴呆ケア学会第4回抄録集, p87. 2003.
 
3) 尾之内直美:家族会から生まれた介護教室, オノウチ式家族支援プログラムによる家族支援, 認知症の人と家族をどうサポートするのか. 訪問看と介護 10 (6):487, 2005.
 
4) 朝田隆:若年性認知症実態と対応の基盤整備に関する研究, 平成18年度～20年度総合研究報告書, p42. 2009.
 
5) 沖田裕子:若年認知症の家族が必要としている支援内容とその時期. 日認知症ケア会誌 5 (3):483-484, 2006.
 
松本一生:家族と学ぶ認知症介護者と支援者のためのガイドブック, 金剛出版東京, 2006.
 
P.241 掲載の参考文献
1) Laurin D, et al:Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch Neurol 58:498-504, 2001.
PubMed
2) Abbott R D, et al:Petrovitch HWalking and dementia in physically capable elderly men. JAMA 292:1447-1453, 2004.
PubMed
3) Larson E R, et al:Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med 144 (2):73-81, 2006.
 
4) Kalmijn S, et al:Dietary fats intake and the risk of incident dementia in the Rotterdam study. Ann Neurol 42:776-782, 1997,
PubMed
5) Barberger-Gateau P, et al:Fish, meat, and risk of dementia:cohort study. BMJ 325:932-933, 2002.
PubMed
6) Engelhart M J, et al:Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 287:3223-3229, 2002. Fratiglioni L, et al:Infiuence of social network on occurrence of dementia;a community-based longitudinal study. Lancet 355:1315-1319, 2000.
 
7) Morris M C, et al:Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 287:3230-3237, 2002.
 
8) Cherubini A, et al:Vitamin E levels, cognitive impairment and dementia in older persons:the InCHIANTI study. Neurobiol Aging 26:987-994, 2005.
PubMed
9) Orgogozo J M, et al:Wine consumption and dementia in the elderly:a prospective community study in the Bordeaux area. Rev Neurol 153:185-192, 1997.
PubMed
10) Lindsay J, et al:Risk factors for Alzheimer's disease:A prospective analysis from the Canadian study of health and aging. Am J Epidemiol 156:445-453, 2002.
PubMed
11) Luchsinger J A, et al:Alcohol intake and risk of dementia J Am Geriatr Soc 52:540-546, 2004.
PubMed
12) Bickel H, et al:Incidence and relative risk of dementia in an urban elderly population; findings of a prospective field study. Psychol Med 24:179-192, 1994.
 
13) Kondo K, et al:A case-control study of Alzheimer's disease in Japan-Significance of life-styles. Dementia 5:314-326, 1994.
PubMed
14) Fratiglioni L, et al:Infiuence of social network on occurrence of dementia; a community-based longitudinal study. Lancet 355:1315-1319, 2000.
 
15) Wilson R S, et al:Cognitive activity and risk of Alzheimer's disease. Curr Direct Psychol Sci 12:87-91, 2003.
 
16) Verghese J, et al:Leisure activities and the risk of dementia in the elderly. N England J Med 348:2508-2516, 2003.
 
17) Ball K, et al:Effects of cognitive training intervention with older adultsl a randomized controlled trial. JAMA 288:2271-2281, 2002.
PubMed
18) Ball K, et al:The impact of speed of processing training on cognitive and everyday functions. J Gerontol B Psychol Sci Soc Sci 62B:19-31, 2007.
 
19) Rozzini L, et al:Efficacy of cognitive rehabilitation in patients with mild cognitive impairment treated with cholinesterase inhibitors. Int J Geriatr Psychiatry 22:356-360, 2007,
PubMed
20) Talassi E, et al:Effectiveness of a cognitive rehabilitation program in mild dementia (MD) and mild cognitive impairment (MCI):a case control study. Arch Gerontol Geriatr 44 (Suppl 1):391-399, 2007.
 
21) Kinsella G J, et al:Early intervention fbr mild cognitive impairment:a randomised controlled trial. J Neurol Neurosurg Psychiatry 80:730-736, 2009.
 
22) Barnes D E, et al:Computer-based cognitive training for Mild Cognitive Impairment:Results from a pilot randomized, controlled trial. Alzheimer Dis Assoc Disord 23:205-210, 2009.
PubMed
23) Belleville S, et al:Improvement of episodic memory in persons with mild cognitive impairment and healthy older adults:evidence from a cognitive intervention program. Dement Geriat Cogn Disord 22 (5-6):486-499, 2006.
 
P.249 掲載の参考文献
1) 斉藤正彦 訳:精神疾患を有する者の保護及びメンタルヘルスケアの改善のための諸原則. 日精病協誌 11 (7):55-64, 1992.
 
2) 厚生省保健医療局精神保健課監修:我が国の精神保健福祉<平成7年度版>, 413-422, 厚健出版, 1996.
 
3) 日本医師会:診療情報の提供に関する指針第2版, 日医会誌 128 (10):付録2002.
 
4) 高橋忍, 他:認知症の病名告知に関する研究:アルツハイマー病痴呆患者への告知に対する医師の意識老年精医誌 16 (9):1049-1055, 2005.
 
5) 認知症介護研究・研修東京センター. 平成 17 年度厚生労働省老人保健事業推進費等補助金事業報告書:認知症の人へのサービス提供のためのインフォームドコンセント実施に関する指針と教育システム開発に関する研究事報告書, 平成18年 3 月.
 
6) 高橋忍, 他:認知症の病名告知に関する研究:アルツハイマー病痴呆患者本人の意向. 老年精医誌 16 (4):471-477, 2005.
 
7) 今井幸満, 他:アルツハイマー病告知の現状と問題点. 老年精医誌・台11 (11):1225-1232, 2000.
 
8) 長濱康弘, 他:痴呆の告知:慎重な立場から. 老年精医誌 15:147-154, 2004.
 
9) 今井幸充:痴呆症の告知;積極的な立場から. 老年精医誌 15:139-146, 2004.
 
10) 北村総子, 他:精神科医療における患者の自己決定権と治療同意判断能力. 学芸社, 東泉, 2000.
 
11) 白石弘巳:医療における高齢者の同意能力. 老年精医誌 13 (10):1121-1126, 2002.
Medical*Online
12) 白石弘巳:医療における高齢者の同意能力. 老年精医誌 13 (10):1121-1126, 2002.
Medical*Online
13) 杉田勇:インフォームド・コンセントとは何か;<特集>病とは何か・癒しとは何かインフォームド・コンセントとは何か. 医哲学医倫理 (13):88-104, 1995.
 
14) 三村將, 他:軽度認知機能障害への対応・訓練:説明と病名告知を含めて. 老年精医誌 (20) 3:287-293, 2009.
 
P.258 掲載の参考文献
1) Arai Y:Implementation and implications of the 2002 Road Traffic Act of Japan from the qualitative study. J Bull Soc Psych 14 (Suppl):158-161, 2006.
 
2) 国家公安委員会:JPS NEWS 75 歳以上の運転者の免許更新. 老年精医誌 20 (1):105-107, 2009.
 
3) 池田学:若年性認知症をめぐる諸問題若年性認知症者の運転免許の問題. 精神医 51 (10):961-966, 2009.
 
4) 上村直人, 他:痴呆性疾患と自動車運転-日本における痴呆患者の自動車運転と家族の対応の実態について-. 脳と神経57(5):409-414, 2005.
 
5) Drachman DA, et al:Driving and Alzheimer's disease;the risk of crashes. Neurology 43:2448-2456, 1993.
PubMed
6) 上村直人, 他:認知症患者の自動車運転の実態と医師の役割. 精神科 11 (1):43-49, 2007.
 
7) 中村重信, 監:痴呆疾患治療ガイドライン 2002. 臨神経 42:781-833, 2002.
 
8) 日本精神神経学会 (監訳):アルツハイマー病と老年期の痴呆-米国精神医学会治療ガイドライン, p36-38. 医学書院東京, 1999.
 
9) 本間昭, 監:かかりつけ医のための痴呆診療マニュアル-医師の倫理・法規と痴呆症診療 (第2版) エーザイ株式会社・ファイザー株式会社, 東京, 2004.
 
10) 新井誠:痴ほうケアなんでも Q and A. 痴ほうケアサポート 8 月号, 2003.
 
11) 国立長寿医療センター長寿政策・在宅医療研究部ホームページ:認知症高齢者の自動車運転を考える家族介護者のための支援マニュアル認知症高齢者の安全と安心のために. (http://www.nils.go.jp/department/dgp/index-dgp-j.htm)
 
P.266 掲載の参考文献
1) 本間 昭:成年後見制度. 臨精神医 37 (5):731-735, 2008.
 
2) 東京家庭裁判所:後見 Q&A 東京家庭裁判所後見サイトhttp://www.courts.go.jp/tokyo-f/saiban/tetuzuki/koken/koken_qa.html
 
3) 最高裁判所事務総局家庭局:成年後見関係事件の概況-平成20年1月～12月-.
 
4) 精神保健福祉研究会:精神保健福祉法詳解, 中央法規, 東京, 2007.
 
5) 成年後見制度における鑑定書・診断書作成の手引. 裁判所ウェブサイトhttp://www.courts.go.jp/saiban/syurui/kazi/kazi_09_02.html
 

第5章 ガイドライン

P.273 掲載の参考文献
1) 中村重信:痴呆疾患の治療ガイドライン. ワールドプランニング, 東京, 2003.
 
2) Suhonen J, et al:Finnish recommendations for best practices in the treatment of progressive memory diseases. Finish Medical Journal 63 (Suppl 10), 2008
 
3) Patterson C, et al:The recognition, assessment and management of dementing disorders:conclusions from the Canadian Consensus Conference on Dementia. Can J Neurol Sci 1 (Suppl 1):S3-16, 2001.
 
4) Knopman D S, et al:Practice parameter:diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56:1143-1153, 2001.
PubMed
5) Dubois B, et al:Research criteria for the diagnosis of Alzheimer's disease:revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734-746, 2007
 
6) Doody R S, et al:Practice parameter:management of dementia (an evidence-based review):Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56:1154-1166, 2001.
PubMed
7) Dubinsky R M, et al:Practice parameter:risk of driving and Alzheimer's disease (an evidence-based review):report of the quality standards subcommittee of the American Academy of Neurology. Neurology 54:2205-2211, 2000.
 

書評

最近チェックした商品履歴

Loading...